Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy

Wei Ding, Yun Ping Li, Lucio M. Mobile, George Grills, Ines Carrera, Elisabeth M. Paietta, Martin S. Tallman, Peter H. Wiernik, Robert E. Gallagher

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

This study evaluated whether relapse of acute promyelocytic leukemia (APL) patients from clinical remissions achieved and/or maintained with all- trans retinoic acid (RA) in combination with intensive chemotherapy is associated with leukemic cellular resistance to RA and with alterations in the PML-RARα fusion gene. We studied matched pretreatment and relapse specimens from 12 patients who received variable amounts of RA, primarily in nonconcurrent combination with daunorubicin and cytarabine (DA) on Eastern Cooperative Oncology Group (ECOG) protocol E2491, and from 8 patients who received DA only on protocol E2491. Of 10 RA-treated patients evaluable for a change in APL cell sensitivity to RA-induced differentiation in vitro, 8 showed diminished sensitivity at relapse, whereas, of 6 evaluable patients treated with DA alone, only 1 had marginally reduced sensitivity. From analysis of sequences encoding the principal functional domains of the PML and RARα portions of PML-RARα, we found missense mutations in relapse specimens from 3 of 12 RA-treated patients and 0 of 8 DA-treated patients. All 3 mutations were located in the ligand binding domain (LBD) of the RARα region of PML-RARα. Relative to normal RARα1, the mutations were Leu290Val, Arg394Trp, and Met413Thr. All pretreatment analyses were normal except for a C to T base change in the 3'-untranslated (UT) region of 1 patient that was also present after relapse from DA therapy. No mutations were detected in the corresponding sequences of the normal RARα or PML (partial) alleles. Minor additional PML-RARα isoforms encoding truncated PML proteins were detected in 2 cases. We conclude that APL cellular resistance occurs with high incidence after relapse from RA + DA therapy administered in a nonconcurrent manner and that mutations in the RARα region of the PML-RARα gene are present in and likely mechanistically involved in RA resistance in a subset of these cases.

Original languageEnglish (US)
Pages (from-to)1172-1183
Number of pages12
JournalBlood
Volume92
Issue number4
StatePublished - Aug 15 1998
Externally publishedYes

Fingerprint

Acid resistance
Acute Promyelocytic Leukemia
Chemotherapy
Gene Fusion
Missense Mutation
Tretinoin
Fusion reactions
Genes
Recurrence
Drug Therapy
Mutation
Therapeutics
Daunorubicin
Oncology
Cytarabine
3' Untranslated Regions
Sequence Analysis
Protein Isoforms
Alleles
Ligands

ASJC Scopus subject areas

  • Hematology

Cite this

Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. / Ding, Wei; Li, Yun Ping; Mobile, Lucio M.; Grills, George; Carrera, Ines; Paietta, Elisabeth M.; Tallman, Martin S.; Wiernik, Peter H.; Gallagher, Robert E.

In: Blood, Vol. 92, No. 4, 15.08.1998, p. 1172-1183.

Research output: Contribution to journalArticle

Ding, Wei ; Li, Yun Ping ; Mobile, Lucio M. ; Grills, George ; Carrera, Ines ; Paietta, Elisabeth M. ; Tallman, Martin S. ; Wiernik, Peter H. ; Gallagher, Robert E. / Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. In: Blood. 1998 ; Vol. 92, No. 4. pp. 1172-1183.
@article{85f036486ff74fc8bd35309d72f477e2,
title = "Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy",
abstract = "This study evaluated whether relapse of acute promyelocytic leukemia (APL) patients from clinical remissions achieved and/or maintained with all- trans retinoic acid (RA) in combination with intensive chemotherapy is associated with leukemic cellular resistance to RA and with alterations in the PML-RARα fusion gene. We studied matched pretreatment and relapse specimens from 12 patients who received variable amounts of RA, primarily in nonconcurrent combination with daunorubicin and cytarabine (DA) on Eastern Cooperative Oncology Group (ECOG) protocol E2491, and from 8 patients who received DA only on protocol E2491. Of 10 RA-treated patients evaluable for a change in APL cell sensitivity to RA-induced differentiation in vitro, 8 showed diminished sensitivity at relapse, whereas, of 6 evaluable patients treated with DA alone, only 1 had marginally reduced sensitivity. From analysis of sequences encoding the principal functional domains of the PML and RARα portions of PML-RARα, we found missense mutations in relapse specimens from 3 of 12 RA-treated patients and 0 of 8 DA-treated patients. All 3 mutations were located in the ligand binding domain (LBD) of the RARα region of PML-RARα. Relative to normal RARα1, the mutations were Leu290Val, Arg394Trp, and Met413Thr. All pretreatment analyses were normal except for a C to T base change in the 3'-untranslated (UT) region of 1 patient that was also present after relapse from DA therapy. No mutations were detected in the corresponding sequences of the normal RARα or PML (partial) alleles. Minor additional PML-RARα isoforms encoding truncated PML proteins were detected in 2 cases. We conclude that APL cellular resistance occurs with high incidence after relapse from RA + DA therapy administered in a nonconcurrent manner and that mutations in the RARα region of the PML-RARα gene are present in and likely mechanistically involved in RA resistance in a subset of these cases.",
author = "Wei Ding and Li, {Yun Ping} and Mobile, {Lucio M.} and George Grills and Ines Carrera and Paietta, {Elisabeth M.} and Tallman, {Martin S.} and Wiernik, {Peter H.} and Gallagher, {Robert E.}",
year = "1998",
month = "8",
day = "15",
language = "English (US)",
volume = "92",
pages = "1172--1183",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy

AU - Ding, Wei

AU - Li, Yun Ping

AU - Mobile, Lucio M.

AU - Grills, George

AU - Carrera, Ines

AU - Paietta, Elisabeth M.

AU - Tallman, Martin S.

AU - Wiernik, Peter H.

AU - Gallagher, Robert E.

PY - 1998/8/15

Y1 - 1998/8/15

N2 - This study evaluated whether relapse of acute promyelocytic leukemia (APL) patients from clinical remissions achieved and/or maintained with all- trans retinoic acid (RA) in combination with intensive chemotherapy is associated with leukemic cellular resistance to RA and with alterations in the PML-RARα fusion gene. We studied matched pretreatment and relapse specimens from 12 patients who received variable amounts of RA, primarily in nonconcurrent combination with daunorubicin and cytarabine (DA) on Eastern Cooperative Oncology Group (ECOG) protocol E2491, and from 8 patients who received DA only on protocol E2491. Of 10 RA-treated patients evaluable for a change in APL cell sensitivity to RA-induced differentiation in vitro, 8 showed diminished sensitivity at relapse, whereas, of 6 evaluable patients treated with DA alone, only 1 had marginally reduced sensitivity. From analysis of sequences encoding the principal functional domains of the PML and RARα portions of PML-RARα, we found missense mutations in relapse specimens from 3 of 12 RA-treated patients and 0 of 8 DA-treated patients. All 3 mutations were located in the ligand binding domain (LBD) of the RARα region of PML-RARα. Relative to normal RARα1, the mutations were Leu290Val, Arg394Trp, and Met413Thr. All pretreatment analyses were normal except for a C to T base change in the 3'-untranslated (UT) region of 1 patient that was also present after relapse from DA therapy. No mutations were detected in the corresponding sequences of the normal RARα or PML (partial) alleles. Minor additional PML-RARα isoforms encoding truncated PML proteins were detected in 2 cases. We conclude that APL cellular resistance occurs with high incidence after relapse from RA + DA therapy administered in a nonconcurrent manner and that mutations in the RARα region of the PML-RARα gene are present in and likely mechanistically involved in RA resistance in a subset of these cases.

AB - This study evaluated whether relapse of acute promyelocytic leukemia (APL) patients from clinical remissions achieved and/or maintained with all- trans retinoic acid (RA) in combination with intensive chemotherapy is associated with leukemic cellular resistance to RA and with alterations in the PML-RARα fusion gene. We studied matched pretreatment and relapse specimens from 12 patients who received variable amounts of RA, primarily in nonconcurrent combination with daunorubicin and cytarabine (DA) on Eastern Cooperative Oncology Group (ECOG) protocol E2491, and from 8 patients who received DA only on protocol E2491. Of 10 RA-treated patients evaluable for a change in APL cell sensitivity to RA-induced differentiation in vitro, 8 showed diminished sensitivity at relapse, whereas, of 6 evaluable patients treated with DA alone, only 1 had marginally reduced sensitivity. From analysis of sequences encoding the principal functional domains of the PML and RARα portions of PML-RARα, we found missense mutations in relapse specimens from 3 of 12 RA-treated patients and 0 of 8 DA-treated patients. All 3 mutations were located in the ligand binding domain (LBD) of the RARα region of PML-RARα. Relative to normal RARα1, the mutations were Leu290Val, Arg394Trp, and Met413Thr. All pretreatment analyses were normal except for a C to T base change in the 3'-untranslated (UT) region of 1 patient that was also present after relapse from DA therapy. No mutations were detected in the corresponding sequences of the normal RARα or PML (partial) alleles. Minor additional PML-RARα isoforms encoding truncated PML proteins were detected in 2 cases. We conclude that APL cellular resistance occurs with high incidence after relapse from RA + DA therapy administered in a nonconcurrent manner and that mutations in the RARα region of the PML-RARα gene are present in and likely mechanistically involved in RA resistance in a subset of these cases.

UR - http://www.scopus.com/inward/record.url?scp=0032529284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032529284&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 1172

EP - 1183

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -